ALACHUA, FL , a biotechnology development company focused on infectious diseases, announced today that it has been selected to receive a $0.5 million grant to advance development of its unique small peptide antibiotic synthesis program using the company's proprietary Differentially Protected Orthogonal Lanthionine Technology (DPOLT(TM)). This two-year Phase II grant, awarded through the Small Business Innovation Research (SBIR) program of the National Science Foundation (NSF), will support studies focused on the synthesis and testing of our lead antibiotic, MU1140(TM).

"Oragenics is very pleased with our success in obtaining this funding," said Dr. Jeffrey Hillman, Chief Scientific Officer and principal investigator for this project. "The recent publicity about hospital-acquired infections and MRSA (methicillin resistant Staphylococcus aureus) has emphasized the tremendous need for new and novel antibiotics to replace the ones that are failing." Successful development of DPOLT(TM) will enable, for the first time, large-scale commercial production of MU1140(TM) and other related antibiotics, which the Company believes will be effective in treating some of the most troublesome human infections. On a related matter, a paper describing the novel mechanism by which MU1140(TM) kills bacteria was recently published in the prestigious international scientific journal "Biochemistry." The "on-line" text of the article was published on February 12, 2008.

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases. Our core pipeline includes products and supporting platform technologies for use in the treatment and diagnosis of bacterial infections.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact: Oragenics, Inc. Dotti Delfino 386-418-4018 X232 www.oragenics.com

Oragenics (AMEX:ONI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Oragenics.
Oragenics (AMEX:ONI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Oragenics.